| |
| |
|
| Insider
Information: |
Spiegelman Daniel K |
| Relationship: |
Director |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
148,092 |
|
|
Indirect Shares
|
6,673 |
|
|
| Direct
Value |
$5,017,406 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
154,765 |
|
|
| Total
Value |
$5,017,406 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
CV Therapeutics Inc |
CVTX |
SVP, CFO |
2009-04-09 |
67,489 |
2009-04-09 |
6,673 |
Premium* |
|
|
Cascadian Therapeutics, Inc |
CASC |
Director |
2018-03-09 |
0 |
2009-12-04 |
0 |
Premium* |
|
|
Biomarin Pharmaceutical Inc |
BMRN |
EVP, Chief Financial O... |
2019-04-30 |
47,686 |
2012-05-29 |
0 |
Premium* |
|
|
Relypsa Inc |
RLYP |
Director |
2016-09-01 |
0 |
2015-06-04 |
0 |
Premium* |
|
|
Myriad Genetics Inc |
MYGN |
Director |
2024-06-04 |
32,917 |
2020-05-27 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
182 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 6 of 8
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2019-03-15 |
4 |
D |
$94.53 |
$683,168 |
D/D |
(7,227) |
55,311 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2015-06-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,042 |
56,686 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2016-05-23 |
4 |
AS |
$87.07 |
$328,184 |
D/D |
(3,769) |
58,644 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2014-05-29 |
4 |
D |
$57.50 |
$218,040 |
D/D |
(3,792) |
59,334 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2017-02-28 |
4 |
OE |
$63.10 |
$1,893,000 |
D/D |
30,000 |
60,347 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2019-03-27 |
4 |
AS |
$90.00 |
$9,000 |
D/D |
(100) |
60,983 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2013-05-01 |
4 |
OE |
$39.06 |
$1,093,680 |
D/D |
28,000 |
61,000 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2018-06-04 |
4 |
D |
$92.07 |
$157,532 |
D/D |
(1,711) |
61,070 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2019-03-22 |
4 |
D |
$88.05 |
$316,804 |
D/D |
(3,598) |
61,083 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2016-05-13 |
4 |
D |
$82.71 |
$142,427 |
D/D |
(1,722) |
62,413 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2019-03-01 |
4 |
D |
$94.76 |
$86,421 |
D/D |
(912) |
62,538 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2018-04-23 |
4 |
AS |
$82.15 |
$908,497 |
D/D |
(11,059) |
62,543 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2018-04-30 |
4 |
A |
$68.78 |
$11,487 |
D/D |
167 |
62,781 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2014-05-15 |
4 |
D |
$57.44 |
$71,283 |
D/D |
(1,241) |
63,126 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2019-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
12,205 |
63,450 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2016-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
16,640 |
63,933 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2016-04-29 |
4 |
A |
$51.26 |
$10,355 |
D/D |
202 |
64,135 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2014-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
26,250 |
64,273 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2014-03-03 |
4 |
AS |
$80.32 |
$642,530 |
D/D |
(8,000) |
64,273 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2014-04-30 |
4 |
A |
$49.50 |
$4,653 |
D/D |
94 |
64,367 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2019-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
9,370 |
64,681 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2018-03-15 |
4 |
D |
$83.57 |
$318,820 |
D/D |
(3,815) |
64,705 |
0 |
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2009-04-09 |
4 |
D |
$19.94 |
$118,643 |
D/D |
(5,950) |
67,489 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2018-03-02 |
4 |
D |
$79.86 |
$128,495 |
D/D |
(1,609) |
68,520 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2014-08-01 |
4 |
S |
$61.76 |
$137,652 |
D/D |
(2,229) |
68,676 |
0 |
- |
|
182 Records found
|
|
Page 6 of 8 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
